1. Optimizing Outcomes and Managing Adverse Events in CLL

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Risk of Bleeding With Ibrutinib

6. Prevention and Management of Bleeding Risk

7. Suggestions for Management of Atrial Fibrillation Associated With Ibrutinib

8. Managing Treatment-Emergent Diarrhea in Patients With CLL

9. Managing Transaminitis Induced by Idelalisib

10. Managing Transaminitis Induced by Idelalisib (cont)

11. Treatment Modification in Relapse Setting

12. Challenges of Idelalisib as Frontline Therapy

13. Managing Idelalisib-Induced Colitis

14. Ibrutinib- and Idelalisib-Induced Pneumonitis

15. Tumor Lysis Syndrome Associated With Venetoclax and Ibrutinib

16. Recommended TLS Prophylaxis Based on Risk Group

17. Major Concern in the Management of TLS Faculty Recommendations

18. Cytopenias Associated With Ibrutinib

19. Management of Ibrutinib-Induced Cytopenias

20. Management of Cytopenias Associated With Venetoclax

21. Cytopenias Associated With Obinutuzumab

22. Prophylaxis for Idelalisib-Induced Infections in Patients With Relapsed/Refractory CLL

23. Infusion Reactions Induced by Obinutuzumab

24. Managing Infusion Reactions Induced by Obinutuzumab

25. Long-Term Complications

26. Long-Term Complications (cont)

27. Interprofessional Care

28. Best Practices for Communication Within a Team

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)